v3.24.1.u1
Significant Agreements - Bristol Myers Squibb Collaboration Agreement (Details)
 3 Months Ended
Jul. 05, 2023
USD ($)
Jul. 30, 2021
USD ($)
Mar. 20, 2018
USD ($)
agreement_term
$ / shares
shares
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration revenue       $ 50,000 $ 2,169,000  
Accounts receivable       0   $ 5,159,000
Deferred revenue, non-current       67,405,000   67,405,000
Collaboration Program, US Rights            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, potential regulatory milestone payments per program     $ 90,000,000      
Collaboration agreement, potential commercial milestone payments per program     375,000,000      
Collaboration Program, US Rights | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, expected allocation of initial transaction price     15,000,000      
Collaboration Program, US Rights | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, expected allocation of initial transaction price     25,000,000      
Collaboration Program, Global Rights            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, potential regulatory milestone payments per program     187,500,000      
Collaboration agreement, potential commercial milestone payments per program     375,000,000      
Collaboration Program, Global Rights | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, expected allocation of initial transaction price     10,000,000      
Collaboration Program, Global Rights | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, expected allocation of initial transaction price     18,000,000      
Collaboration revenue            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration revenue       0 2,119,000  
Bristol Myers Squibb            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, potential regulatory and commercial milestone payments per program     $ 562,500,000      
Collaboration agreement, number of additional 12 month period extension allowed | agreement_term     2      
Collaboration agreement, extension fee per extension period     $ 10,000,000      
Collaboration revenue       0 $ 2,100,000  
Deferred Revenue       67,400,000    
Bristol Myers Squibb | Collaboration Program, US Rights            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, exercise fee per program     80,000,000      
Bristol Myers Squibb | Collaboration Program, Global Rights            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, exercise fee per program     55,000,000      
Bristol Myers Squibb | Collaboration Revenue, US License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Allocated consideration to performance obligations   $ 77,500,000        
Bristol Myers Squibb | Collaboration Revenue, US Development Services            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Allocated consideration to performance obligations   27,500,000        
Bristol Myers Squibb | Collaboration Program, Global, Tau/ PRX005            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, potential regulatory and commercial milestone payments per program $ 562,500,000          
Collaboration Agreement, Allocation of Initial Transaction Price 17,900,000          
Collaboration Program, Global Exercise Fee 55,000,000          
Collaboration Agreement, Total Transaction Price, PRX005 Global $ 72,900,000          
Bristol Myers Squibb | Collaboration Program, US, Tau/ PRX005            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration Agreement, Allocation of Initial Transaction Price     24,900,000      
Collaboration Agreement, Total Transaction Price, PRX005 US   104,900,000        
Collaboration Program, PRX005 US License Agreement, Upfront Payment   $ 80,000,000        
BMS (formerly Celgene)            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, upfront payment     $ 100,000,000      
Collaboration agreement, option fees and milestone payments, payment term     30 days      
BMS (formerly Celgene) | Private Placement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Share subscription agreement, number of ordinary shares issued in transaction (in shares) | shares     1,174,536      
Share subscription agreement, price per share (in dollars per share) | $ / shares     $ 42.57      
Share subscription agreement, consideration received on transaction     $ 50,000,000      
Share subscription agreement, premium received on transaction     10,200,000      
Collaborative Arrangement | Bristol Myers Squibb            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Accounts receivable       0   $ 5,200,000
Revenue, Remaining performance obligation, Amount       $ 0    
Collaborative Arrangement | BMS (formerly Celgene)            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration agreement, Initial transaction price     $ 110,200,000